talzenna
pfizer europe ma eeig - talazoparib - bryst neoplasmer - antineoplastiske midler - talzenna er angivet som monoterapi til behandling af voksne patienter med germline brca1/2 mutationer, der har her2-negative lokalt fremskreden eller metastatisk brystkræft. patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. patienter med hormon receptor (hr)-positiv brystkræft skulle have været behandlet med en forudgående endokrine-baseret terapi, eller anses uegnet til at endokrine-baseret terapi.
nilemdo
daiichi sankyo europe gmbh - bempedoic syre - hypercholesterolemia; dyslipidemias - lipid modificerende midler - nilemdo er indiceret hos voksne med primær hypercholesterolaemia (heterozygote familiær og ikke-familiær) eller blandet dyslipidaemia, som et supplement til kost:i kombination med et statin eller statin med andre lipidsænkende behandlinger på patienter i stand til at nå ldl-c mål med den maksimalt tolererede dosis af et statin (se afsnit 4. 2, 4. 3 og 4. 4) eller,alene eller i kombination med andre lipidsænkende behandlinger på patienter, der er statin intolerant, eller for hvem en statin-præparat er kontraindiceret.
daurismo
pfizer europe ma eeig - glasdegib maleate - leukæmi, myeloid, akut - antineoplastiske midler - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.
nuvaxovid
novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. brug af denne vaccine bør være i overensstemmelse med de officielle anbefalinger.
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukæmi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.
apotel 10 mg/ml infusionsvæske, opløsning
uni-pharma kleon - paracetamol - infusionsvæske, opløsning - 10 mg/ml
ezimvalla 10+10 mg tabletter
zentiva k.s. - ezetimib, simvastatin - tabletter - 10+10 mg
ezimvalla 10+20 mg tabletter
zentiva k.s. - ezetimib, simvastatin - tabletter - 10+20 mg
ezimvalla 10+40 mg tabletter
zentiva k.s. - ezetimib, simvastatin - tabletter - 10+40 mg
ezimvalla 10+80 mg tabletter
zentiva k.s. - ezetimib, simvastatin - tabletter - 10+80 mg